Arterial Hypertension as a Risk Comorbidity Associated with COVID-19 Pathology
Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), is an ongoing global public health challenge. Current clinical data suggest that, in COVID-19 patients, arterial hypertension (AH) is one of the most common cardiovascul...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | International Journal of Hypertension |
| Online Access: | http://dx.doi.org/10.1155/2020/8019360 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849467469314392064 |
|---|---|
| author | Alexander Kamyshnyi Inna Krynytska Victoriya Matskevych Mariya Marushchak Oleh Lushchak |
| author_facet | Alexander Kamyshnyi Inna Krynytska Victoriya Matskevych Mariya Marushchak Oleh Lushchak |
| author_sort | Alexander Kamyshnyi |
| collection | DOAJ |
| description | Coronavirus disease 2019 (COVID-19), caused by the novel coronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), is an ongoing global public health challenge. Current clinical data suggest that, in COVID-19 patients, arterial hypertension (AH) is one of the most common cardiovascular comorbidities; it can worsen outcomes and increase the risk of admission to intensive care unit (ICU). The exact mechanisms through which AH contributes to the poor prognosis in COVID-19 are not yet clear. The putative relationship between AH and COVID-19 may be linked to the role of angiotensin-converting enzyme 2 (ACE2), a key element of the AH pathophysiology. Another mechanism connecting AH and COVID-19 is the dysregulation of the immune system resulting in a cytokine storm, mediated by an imbalanced response of T helper cells subtypes. Therefore, it is essential to optimize blood pressure control in hypertensive patients and monitor them carefully for cardiovascular and other complications for the duration of COVID-19 infection. The question whether AH-linked ACE2 gene polymorphisms increase the risk and/or worsen the course of SARS-CoV-2 infection should also receive further consideration. |
| format | Article |
| id | doaj-art-e6e56619a5394e77ad459b20fc4be0bd |
| institution | Kabale University |
| issn | 2090-0384 2090-0392 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Hypertension |
| spelling | doaj-art-e6e56619a5394e77ad459b20fc4be0bd2025-08-20T03:26:11ZengWileyInternational Journal of Hypertension2090-03842090-03922020-01-01202010.1155/2020/80193608019360Arterial Hypertension as a Risk Comorbidity Associated with COVID-19 PathologyAlexander Kamyshnyi0Inna Krynytska1Victoriya Matskevych2Mariya Marushchak3Oleh Lushchak4Department of Microbiology, Virology and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, UkraineDepartment of Functional and Laboratory Diagnostics, I. Horbachevsky Ternopil National Medical University, Ternopil, UkraineDepartment of Radiology and Radiation Medicine, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, UkraineDepartment of Functional and Laboratory Diagnostics, I. Horbachevsky Ternopil National Medical University, Ternopil, UkraineDepartment of Biochemistry and Biotechnology, Vasyl Stefanyk Precarpathian National University, Ivano-Frankivsk, UkraineCoronavirus disease 2019 (COVID-19), caused by the novel coronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), is an ongoing global public health challenge. Current clinical data suggest that, in COVID-19 patients, arterial hypertension (AH) is one of the most common cardiovascular comorbidities; it can worsen outcomes and increase the risk of admission to intensive care unit (ICU). The exact mechanisms through which AH contributes to the poor prognosis in COVID-19 are not yet clear. The putative relationship between AH and COVID-19 may be linked to the role of angiotensin-converting enzyme 2 (ACE2), a key element of the AH pathophysiology. Another mechanism connecting AH and COVID-19 is the dysregulation of the immune system resulting in a cytokine storm, mediated by an imbalanced response of T helper cells subtypes. Therefore, it is essential to optimize blood pressure control in hypertensive patients and monitor them carefully for cardiovascular and other complications for the duration of COVID-19 infection. The question whether AH-linked ACE2 gene polymorphisms increase the risk and/or worsen the course of SARS-CoV-2 infection should also receive further consideration.http://dx.doi.org/10.1155/2020/8019360 |
| spellingShingle | Alexander Kamyshnyi Inna Krynytska Victoriya Matskevych Mariya Marushchak Oleh Lushchak Arterial Hypertension as a Risk Comorbidity Associated with COVID-19 Pathology International Journal of Hypertension |
| title | Arterial Hypertension as a Risk Comorbidity Associated with COVID-19 Pathology |
| title_full | Arterial Hypertension as a Risk Comorbidity Associated with COVID-19 Pathology |
| title_fullStr | Arterial Hypertension as a Risk Comorbidity Associated with COVID-19 Pathology |
| title_full_unstemmed | Arterial Hypertension as a Risk Comorbidity Associated with COVID-19 Pathology |
| title_short | Arterial Hypertension as a Risk Comorbidity Associated with COVID-19 Pathology |
| title_sort | arterial hypertension as a risk comorbidity associated with covid 19 pathology |
| url | http://dx.doi.org/10.1155/2020/8019360 |
| work_keys_str_mv | AT alexanderkamyshnyi arterialhypertensionasariskcomorbidityassociatedwithcovid19pathology AT innakrynytska arterialhypertensionasariskcomorbidityassociatedwithcovid19pathology AT victoriyamatskevych arterialhypertensionasariskcomorbidityassociatedwithcovid19pathology AT mariyamarushchak arterialhypertensionasariskcomorbidityassociatedwithcovid19pathology AT olehlushchak arterialhypertensionasariskcomorbidityassociatedwithcovid19pathology |